India limits drug trials per investigator but finite expert pool a concern

This article was originally published in SRA

10 Jul 2014
News

Anju Ghangurde @ScripAnjuG anju.ghangurde@informa.com

Executive Summary

India's Central Drugs Standard Control Organization has issued a new order that restricts the number of clinical trials that an investigator can be involved in to no more than three trials at a time¹. The order, issued this month, has come under fire from the Indian Society for Clinical Research, which warns it will be "detrimental" to the progress of quality clinical research in the country.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS117860

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS117860

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

India limits drug trials per investigator but finite expert pool a concern

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert